Semisynthetic polymyxins with potent antibacterial activity and reduced kidney cell toxicity-Reference-Cited by-同舟云学术

Semisynthetic polymyxins with potent antibacterial activity and reduced kidney cell toxicity

Published:2023 Issue:11 Volume:14 Page:2417-2425
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Slingerland Cornelis J.¹^ORCID,Lysenko Vladyslav¹,Chaudhuri Samhita¹,Wesseling Charlotte M. J.¹,Barnes Devon²,Masereeuw Rosalinde²^ORCID,Martin Nathaniel I.¹^ORCID

Affiliation:

1. Biological Chemistry Group, Institute of Biology Leiden, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands

2. Division of Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, The Netherlands

Abstract

A novel series of polymyxin analogues bearing a disulfide linked lipid tail are reported. The most promising variant identified exhibits antibacterial activity equipotent to that of polymyxin B and is >10-fold less toxic towards kidney cells.

Funder

H2020 European Research Council

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MD/D3MD00456B

Reference38 articles.

1. World Health Organization , Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis , WHO , Geneva , 2017

2. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

3. Antibiotic development — economic, regulatory and societal challenges

4. Platforms for antibiotic discovery

5. GSK, Gepotidacin's positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years, https://www.gsk.com/en-gb/media/press-releases/gepotidacin-s-positive-phase-iii-data-shows-potential-to-be-the-first-in-a-new-class-of-oral-antibiotics-for-uncomplicated-urinary-tract-infections/ , (accessed 12 July 2023 )